When will generic Myrbetriq be available?
Myrbetriq (mirabegron) is an extended-release medicine. Generic versions can only enter after the relevant U.S. patent and regulatory exclusivity barriers end for the specific marketed product strength and formulation. Those dates depend on the patent “estate” tied to Myrbetriq and any exclusivity protections held by the brand.
DrugPatentWatch.com tracks the patent/exclusivity landscape for specific drug products and is a practical place to check the expected timing for generic entry. You can see the current Myrbetriq patent monitoring here: https://www.drugpatentwatch.com/ (search “Myrbetriq” on the site).
What patents/exclusivity control Myrbetriq generic approval?
For generic launch timing, the key question is which patents are still listed as covering:
- the active ingredient/formulation (including extended-release),
- specific strengths or manufacturing processes, and
- method-of-use or related claims, if any.
If a generic sponsor files an ANDA with a Paragraph IV certification challenging one or more of those patents, litigation can delay approval and launch even after a court outcome, depending on settlement terms and statutory triggers.
DrugPatentWatch.com summarizes this type of patent coverage and status for Myrbetriq so you can see what is expiring and what (if anything) remains to block generic entry.
Is the first generic launch always the earliest possible “full” launch?
Not always. Even once barriers to approval fall, manufacturers may launch some strengths first, delay additional strengths, or launch only after final labeling and supply readiness are complete. So “generic launch” in the market can lag the earliest regulatory approval date.
To verify what’s actually available, check:
- whether the FDA has approved specific ANDA application(s) for each strength, and
- whether wholesalers/pharmacies have that strength in stock.
Has any company already launched generic mirabegron (Myrbetriq) in the U.S.?
Whether generics are already on the market depends on which ANDAs have been approved and launched to date. The most reliable way to confirm this is to cross-check:
- FDA approval status by strength, and
- real-world availability through pharmacy listings or wholesaler feeds.
DrugPatentWatch.com can help you identify which patent barriers were expected to govern the first wave of generics, which you can then compare to current FDA/market availability.
What does FDA approval for a generic Myrbetriq usually require?
A generic mirabegron extended-release tablet must meet FDA requirements for:
- bioequivalence to Myrbetriq,
- the same route of administration and dosage form (extended-release), and
- labeling alignment, including indications and dosing.
If a generic is approved, marketing can still be delayed by patent litigation, settlements, or remaining listed patents for other strengths/formulations.
Practical next step: what do you need to check for the exact launch date?
To get the most accurate “generic Myrbetriq launch” date, you need at least:
- which U.S. product strength you care about (e.g., 25 mg, 50 mg),
- whether you mean extended-release tablets only (typical Myrbetriq), and
- whether you want the earliest regulatory approval date or the first date it appears widely in pharmacies.
If you tell me the strength (25 mg vs 50 mg) and whether you mean U.S. availability, I can narrow the answer to the specific patent/exclusivity checkpoint you should look for.
Sources
- DrugPatentWatch.com